Skip Navigation Links  
 

Dr. Aisen's Selected Publications



Paul S. Aisen M.D.

Director, Alzheimer's Disease Cooperative Study

Professor, Department of Neurosciences, UCSD

 AuthorTitleJournal CitationYear
SelectAisen PSLeon Thal and the therapeutic age of Alzheimer’s disease.Alzheimer’s & Dementia, 4: S4-62008
SelectAisen PSTreatment for MCI: is the evidence sufficient?Neurology, 70: 2020-12008
SelectAisen PSThe Inflammatory Hypothesis of Alzheimer’s Disease: Dead or Alive?Alzheimer’s Disease and Associated Disorders, 22: 4-52008
SelectAisen PSAn aspirin a day for Alzheimer’s disease?Lancet Neurology, 7:20-212008
SelectAisen PSTarenflurbil: a shot on goal.Lancet Neurology, 7: 468-92008
SelectDoody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D, and the Dimebon InvestigatorsDimebon improves cognition, behaviour, activities of daily living and global function in a randomised, double-blind, placebo-controlled 6-month study of patients with mild-to-moderate Alzheimer’s disease.Lancet, 371: 207-2152008
SelectFleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack Jr CR, Aisen PS, Thal LJ for the Alzheimer’s Disease Cooperative StudyVolumetric MRI versus clinical predictors of Alzheimer’s disease in Mild Cognitive Impairment.Neurology, 70:191-1992008
SelectMatsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li H-F, Feng L, Lecanu L, Walker Planel E, Arancio O, Gozes I, Aisen PSA neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease.Journal of Pharmacological and Experimental Therapeutics, 325: 146-1532008
SelectTractenberg RE, Aisen PS, Hancock GR, William Rebeck GNo cross-sectional influence of APOE varepsilon4 dose on clinical tests in Alzheimer's disease.Neurobiol Aging, in press2008
SelectAisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giulani MJ, Lines CR, Norman BA, Potter WZRofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.Current Alzhimer’s Research, 5, 73-822008